Loading...

Home
ETF
NAMS

NAMS

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NAMS News

NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)

NewAmsterdam Pharma Releases FY 2025 Financial Results

Feb 18 2026seekingalpha

NewAmsterdam Pharma Reports Clinical Progress and Financial Update

Feb 18 2026Yahoo Finance

NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost

Jan 16 2026NASDAQ.COM

NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26

Jan 09 2026Newsfilter

NewAmsterdam Grants 40,000 Share Options to Attract New Hires

Dec 05 2025Globenewswire

HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52

Oct 20 2025Benzinga

Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies

Sep 15 2025NASDAQ.COM

NewAmsterdam Pharma Company N.V. (NAMS) Shares Insights at Citi's Biopharma Back to School Conference Transcript

Sep 04 2025Newsfilter

Wells Fargo Begins Coverage of NewAmsterdam Pharma Co with Overweight Rating and Sets Price Target at $45

Aug 25 2025Benzinga

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

Aug 24 2025PRnewswire

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

Aug 22 2025PRnewswire

Piramal Pharma Solutions and NewAmsterdam Pharma Collaborate to Upgrade Oral Solid Dosage Production Facilities at Piramal's Sellersville, Pennsylvania Location

Aug 21 2025Newsfilter

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 21 2025PRnewswire

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

Jul 31 2025Newsfilter

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30 2025Newsfilter